Medicus 2014;23(2):111-116
115
LITERATURA
1.
Brooks PM. The burden of musculoskeletal disease – a global
perspective. Clin Rheumatol 2006;25:778–81.
2.
Siddall PJ, Cousins MJ. Persistent pain as a disease entity: impli-
cations for clinical management. Anesth Analg 2004;99:510–20.
3.
Wisconsin Medical Society Task Force on Pain Management.
Guidelines for the assessment and management of chronic
pain. WMJ 2004;103:13–42.
4.
Harkness EF, Macfarlane GJ, Silman AJ, McBeth J. Is muscu-
loskeletal pain more common now than 40 years ago?: two
population-based cross-sectional studies. Rheumatology
2005;44:890–5.
5.
Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Sur-
vey of chronic pain in Europe: prevalence, impact on daily life,
and treatment. Eur J Pain 2006;10:287–333.
6.
Smith BH, Elliott AM, Chambers WA, SmithWC, Hannaford PC,
Penny K. The impact of chronic pain in the community. Fam
Pract 2001:18:292–9.
7.
Van der Windt D. The symptom of pain in populations. U: Croft
P, Blyth FM, van der Windt D, ur. Chronic Pain Epidemiology.
From Aetiology to Public Health. New York: Oxford University
Press, 2010, str. 137.
8.
Natvig B, Rutle O, Bruusgaard D, Eriksen WB. The association
between functional status and the number of areas in the body
withmusculoskeletal symptoms. Int JRehabil Res 2000;23:49–53.
9.
Ten Klooster PM, Veehof MM, Taal E, van Riel PL, van de Laar
MA. Changes in priorities for improvement in patients with
rheumatoid arthritis during one year of anti-TNF treatment.
Ann Rheum Dis 2007; 66: 1485–90.
10. Larsson B, Björk J, Börsbo B, Gerdle B. A systematic review of risk
factors associatedwith transitioning fromregional musculoskele-
tal pain to chronic widespread pain. Eur J Pain 2012; 16: 1084–93.
11. Mallen CD, Peat G, Thomas E i sur. Prognostic factors for mus-
culoskeletal pain in primary care: a systematic review. Br J Gen
Pract 2007;57:655–61.
12. Linton SJ, Halldén K. Can we screen for problematic back pain?
A screening questionnaire for predicting outcome in acute and
subacute back pain. Clin J Pain 1998;14:209–15.
13. Kuijpers T, van der Windt DA, van der Heijden GJ, Twisk JW,
Vergouwe Y, Bouter LM. A prediction rule for shoulder pain re-
lated sick leave: a prospective cohort study. BMCMusculoskelet
Disord 2006;7:97.
14. Borenstein D. The role of the rheumatologist in managing pain
therapy. Nat Rev Rheumatol 2010;6:227–31.
15. World Health Organization. Cancer pain relief. Geneva:WHO,
1996.
16. Crofford LJ. Adverse effects of chronic opioid therapy for chro-
nic musculoskeletal pain. Nat Rev Rheumatol 2010;6:191–7.
17. Hochberg MC, Altman RD, April KT i sur. American College of
Rheumatology 2012 recommendations for the use of nonphar-
macologic and pharmacologic therapies in osteoarthritis of the
hand, hip, and knee. Arthritis Care Res 2012;64:465–74.
18. Zhang W, Doherty M, Leeb BF i sur. EULAR evidence based re-
commendations for the management of hand osteoarthritis:
report of a Task Force of the EULAR Standing Committee for
International Clinical Studies Including Therapeutics (ESCI-
SIT). Ann Rheum Dis 2007;66:377–88.
19. Zhang W, Doherty M, Arden N i sur. EULAR evidence based
recommendations for the management of hip osteoarthritis:
report of a task force of the EULAR Standing Committee for In-
ternational Clinical Studies Including Therapeutics (ESCISIT).
Ann Rheum Dis 2005;64:669–681.
20. National Institute for Health and Clinical Excellence (NICE).
Osteoarthritis: the care and management of osteoarthritis in
adults. NICE clinical guideline 59. London: NICE;2008.
21. Smith HS. Potential analgesic mechanisms of acetaminophen.
Pain Physician 2009;12:269–80.
22. Botting RM. Mechanism of action of acetaminophen: is there a
cyclooxygenase 3? Clin Infect Dis 2000;31Suppl 5:202–10.
23. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Com-
parison of an anti-inflammatory dose of ibuprofen, an anal-
gesic dose of ibuprofen, and acetaminophen in the treatment
of patients with osteoarthritis of the knee. N Engl J Med.
1991;325:87–91.
24. Lee C, Straus WL, Balshaw R, Barlas S, Vogel S, Schnitzer TJ. A
comparison of the efficacy and safety of nonsteroidal antiinflam-
matory agents versus acetaminophen in the treatment of osteoar-
thritis: ameta-analysis. Arthritis Rheum 2004;51:746–54.
25. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminop-
hen) reduce the pain of osteoarthritis? A meta-analysis of ran-
domised controlled trials. Ann Rheum Dis 2004;63:901–7.
26. Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminop-
hen in treating symptomatic knee osteoarthritis: a randomi-
zed, double-blind, placebo-controlled comparison trial with
diclofenac sodium. Arch Intern Med 2003;163:169–78.
27. Pincus T, Koch GG, Sokka T i sur. A randomized, doubleblind,
crossover clinical trial of diclofenac plus misoprostol versus
acetaminophen in patients with osteoarthritis of the hip or
knee. Arthritis Rheum. 2001;44:1587–98.
28. García Rodríguez LA, Hernández-Díaz S. The risk of upper ga-
strointestinal complications associated with nonsteroidal an-
ti-inflammatory drugs, glucocorticoids, acetaminophen, and
combinations of these agents. Arthritis Res 2001;3:98–101.
29. Watkins PB, Kaplowitz N, Slattery JT i sur. Aminotransfera-
se Elevations in Healthy Adults Receiving 4 Grams of Ace-
taminophen Daily. A Randomized Controlled Trial. JAMA
2006;296:87–93.
30. Budd K. Monoamine function and analgesia. Pain reviews
1994;1:3–8.
31. Schnitzer TJ, Kamin M, Olson WH. Tramadol allows reduction
of naproxen dose among patients with naproxen-responsive
osteoarthritis pain: a randomized, double-blind, placebo-con-
trolled study. Arthritis Rheum 1999; 42:1370–7.
32. Mullican WS, Lacy JR; TRAMAP-ANAG-006 Study Group:
Tramadol/acetaminophen combination tablets and codeine/
Liječenjemišićno-koštane boli
